MYB and MYC phosphorylation were synergistically suppressed in KIT-mutant FDC-P1 AML cells by the combination of the Src/KIT inhibitor dasatinib with the DNA-PK inhibitor nedisertib[171]. Here, MYB is linked to acute myeloid leukemia.